 |
Clinical Challenges in RA Management: Addressing Treatment Failure CME/CE Author Information and Disclosures Release Date: June 23, 2008; Valid for credit through June 23, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.5 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Recognize the tools used for patient monitoring and criteria that define and monitor disease progression/treatment success or failure
- Consider the benefits and limitations of further antitumor necrosis factor (anti-TNF) therapy vs other types of rheumatoid
arthritis (RA) therapy following inadequate response to an anti-TNF agent
- Recognize the importance of patient selection and treatment plan development based on patient preferences
- Develop appropriate treatment algorithms for patients following an inadequate response to an anti-TNF agent for RA
Authors and Disclosures
Stephen A. Paget, MD
Disclosure: Stephen A. Paget, MD, has disclosed that he has served as a consultant for Pfizer, Abbott, Genentech, and Pfizer. Dr. Paget has also disclosed that he has served as chair of the Data Safety and Monitoring Board of Medarex. Jonathan Kay, MD, FACP, FACR
Disclosure: Jonathan Kay, MD, FACP, FACR, has disclosed that he has received grants for clinical
research from Amgen, Centocor, Genentech, Novartis, and Pfizer, and has received grants for educational activities from Amgen, Array BioPharma, Biogen Idec, Centocor, Genentech, Roche, and Wyeth. Sergio Schwartzman, MD
Disclosure: Sergio Schwartzman, MD, has disclosed that he has served as a consultant or speaker for Centocor, Abbott, UCB, and Genentech. Helen Fosam, PhD
Disclosure: Helen Fosam, PhD, has disclosed no relevant financial relationships. Jayashree Gokhale, PhD
Disclosure: Jayashree Gokhale, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
